The pharmacokinetic effects of coadministration of morphine and trovafloxacin in healthy subjects

American Journal of Surgery

Volumn 176, Issue 6 A, 1998, Pages 32S-38S

  Vincent, John ^a   Hunt, Thomas ^a,b   Teng, Renli ^a,c   Robarge, Lisa ^a   Willavize, Susan A ^a   Friedman, Hylar L ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

^b PPD Pharmaco   (United States)

^c Astra Merck   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MORPHINE; PLACEBO; TROVAFLOXACIN;

ADULT; ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC THERAPY; ANTIMICROBIAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BIOAVAILABILITY; CLINICAL TRIAL; CONCENTRATION RESPONSE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG TOLERABILITY; FEMALE; HUMAN; HUMAN EXPERIMENT; INTRAVENOUS DRUG ADMINISTRATION; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0032450458     PISSN: 00029610     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9610(98)00218-9     Document Type: Article

References (28)

1. von Rosenstiel N, Adam D. Quinolone antibacterials: an update of their pharmacology and therapeutic use. Drugs. 1994;47:872-901.
2. Neu HC, Chin N-X. In vitro activity of the new fluoroquinolone CP-99,219. Antimicrob Agents Chemother. 1994;38:2615-2622.
3. Blumberg HM, Rimland D, Carroll DJ, et al. Rapid development of ciprofloxacin resistance in methicillin-susceptible and -resistant Staphylococcus aureus. J Infect Dis. 1991;163:1279-1285.
4. Kaatz GW, Seo SM, Ruble CA. Mechanisms of fluoroquinolone resistance in Staphylococcus aureus. J Infect Dis. 1991;163:1080-1086.
5. Jones RN. In vitro antimicrobial activity of CP-99,219, a new 7-azabicyclonaphthyridone. Drugs. 1995;49(suppl 2):205-207.
6. Moellering RC Jr. Quinolone antimicrobial agents: overview and conclusions. In: Wolfson JS, Hooper DC, eds. Quinolone Antimicrobial Agents. Washington, DC: American Society for Microbiology; 1989:273-283.
7. Felmingham D, Robbins MJ, Ingley K, et al. In vitro activity of trovafloxacin, a new fluoroquinolone, against recent clinical isolates. J Antimicrob Chemother. 1997;39(suppl B):43-49.
8. Girard AE, Girard D, Gootz TD, et al. In vivo efficacy of trovafloxacin (CP-99,219), a new quinolone with extended activities against gram-positive pathogens, Streptococcus pneumoniae, and Bacteroides fragilis. Antimicrob Agents Chemother. 1995;39:2210-2216.
9. Coque TM, Singh KV, Murray BE. Comparative in-vitro activity of the new fluoroquinolone trovafloxacin (CP-99,219) against gram-positive cocci. J Antimicrob Ther. 1996;37:1011-1016.
10. Snydman DR, McDermott L. Analysis of the in vitro activity of trovafloxacin (CP-99,219) against Bacteroides species. Infect Dis Clin Pract. 1996;5(suppl 3):S96-S100.
11. Gorbach SL, Bartlett JG. Anaerobic infections. N Engl J Med. 1974;290:1177-1184, 1237-1245, 1289-1294.
12. Teng R, Harris SC, Nix DE, et al. Pharmacokinetics and safety of trovafloxacin (CP-99,219), a new quinolone antibiotic, following administration of single oral doses to healthy male volunteers. J Antimicrob Chemother. 1995;36:385-394.
13. Teng R, Liston TE, Harris SC. Multiple-dose pharmacokinetics and safety of trovafloxacin in healthy volunteers. J Antimicrob Chemother. 1996;37:955-963.
14. Teng R, Dogolo LC, Willavize SA, et al. Oral bioavailability of trovafloxacin with and without food in healthy male volunteers. J Antimicrob Chemother. 1997;39(suppl B):87-92.
15. Bergeron MG. The pharmacokinetics and tissue penetration of the fluoroquinolones. Clin Invest Med. 1989;12:20-27.
16. Teng R, Dogolo LC, Willavize SA, Vincent J. Effect of age and gender on the pharmacokinetics of CP-99,219, a new quinolone antibiotic, in healthy volunteers (Abstract F238). In: Abstracts of the Thirty-fifth Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1995:154.
17. Vincent J, Teng R, Dogolo LC, et al. Effect of trovafloxacin, a new fluoroquinolone antibiotic, on the steady-state pharmacokinetics of theophylline in healthy volunteers. J Antimicrob Chemother. 1997;39(suppl B):81-86.
18. Jaffe JH, Martin WR. Opioid analgesics and antagonists. In: Goodman Oilman A, Rail TW, Nies AS, Taylor P, eds. Goodman and Gilman's The Pharmacological Basis of Therapeutics. 8th ed. Elmsford, NY: Pergamon Press, 1990:485-521.
19. Brighty KE, Gootz TD, Girard A, et al. Prodrugs of CP-99,219 for intravenous administration; synthesis and evaluation resulting in identification of CP-116,517 (Abstract 730). In: Abstracts of the 7th European Congress of Clinical Microbiology and Infectious Diseases. Amsterdam: CONIFER, Excerpta Medica Medical Communications b.v.; 1995:141.
20. Williams DJ, Hopkins S. Safety and tolerability of intravenous to oral treatment and single dose intravenous or oral prophylaxis with trovafloxacin. Am J Surg. 1998;176(Suppl 6A):74S-79S.
21. Morran C, McArdle CS, Pettit L, et al. Brief report: pharmacokinetics of orally administered ciprofloxacin in abdominal surgery. Am J Med. 1989;87(suppl 5A):86S-88S.
22. Melnick G, Schwesinger H, Dogolo LC, et al. Concentrations of trovafloxacin in colonic tissue and peritoneal fluid after intravenous infusion of the prodrug alatrofloxacin in patients undergoing colorectal surgery. Am J Surg. 1998;176(Suppl 6A):14S-17S.
23. Kenny GE, Cartwright FD. Susceptibilities of Mycoplasma pneumoniae, Mycoplasma hominis, and Ureaplasma urealyticum to a new quinolone, trovafloxacin (CP-99,219). Antimicrob Agents Chemother. 1996;40:1048-1049.
24. Endtz HP, Mouton JW, Den Hollander JG, et al. Comparative in vitro activities of trovafloxacin (CP-99,219) against 445 gram-positive isolates from patients with endocarditis and those with other bloodstream infections. Antimicrob Agents Chemother. 1997; 41:1146-1149.
25. Brighty KE, Gootz TD. The chemistry and biological profile of trovafloxacin. J Antimicrob Chemother. 1997;39(suppl B):1-14.
26. Spangler SK, Jacobs MR, Appelbaum PC. Activity of CP 99,219 compared with those of ciprofloxacin, grepafloxacin, metronidazole, cefoxitin, piperacillin, and piperacillin-tazobactam against 489 anaerobes. Antimicrob Agents Chemother. 1994;38: 2471-2476.
27. Thompson Pl, Joel SP, John L, et al. Respiratory depression following morphine and morphine-6-glucuronide in normal subjects. Br J Clin Pharmacol. 1995;40:145-152.
28. Rowland M, Tozer TN. Clinical Pharmacokinetics: Concepts and Application. Philadelphia: Lea & Febiger; 1980.